These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29523800)

  • 41. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup.
    Woollacott IOC; Nicholas JM; Heslegrave A; Heller C; Foiani MS; Dick KM; Russell LL; Paterson RW; Keshavan A; Fox NC; Warren JD; Schott JM; Zetterberg H; Rohrer JD
    Alzheimers Res Ther; 2018 Aug; 10(1):79. PubMed ID: 30111356
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Amyloid-β42/Neurogranin Ratio as a Potential Index for Cognitive Impairment in Parkinson's Disease.
    Sancesario GM; Di Lazzaro G; Alwardat M; Biticchi B; Basile V; Salimei C; Colona VL; Sinibaldi Salimei P; Bernardini S; Mercuri NB; Pisani A; Schirinzi T
    J Alzheimers Dis; 2020; 76(3):1171-1178. PubMed ID: 32597810
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease.
    Thorsell A; Bjerke M; Gobom J; Brunhage E; Vanmechelen E; Andreasen N; Hansson O; Minthon L; Zetterberg H; Blennow K
    Brain Res; 2010 Nov; 1362():13-22. PubMed ID: 20875798
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis.
    Scahill RI; Zeun P; Osborne-Crowley K; Johnson EB; Gregory S; Parker C; Lowe J; Nair A; O'Callaghan C; Langley C; Papoutsi M; McColgan P; Estevez-Fraga C; Fayer K; Wellington H; Rodrigues FB; Byrne LM; Heselgrave A; Hyare H; Sampaio C; Zetterberg H; Zhang H; Wild EJ; Rees G; Robbins TW; Sahakian BJ; Langbehn D; Tabrizi SJ
    Lancet Neurol; 2020 Jun; 19(6):502-512. PubMed ID: 32470422
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia.
    Willemse EAJ; Sieben A; Somers C; Vermeiren Y; De Roeck N; Timmers M; Van Broeckhoven C; De Vil B; Cras P; De Deyn PP; Martin JJ; Teunissen CE; Engelborghs S; Bjerke M
    Neurobiol Aging; 2021 Dec; 108():99-109. PubMed ID: 34551375
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Large-scale brain network abnormalities in Huntington's disease revealed by structural covariance.
    Minkova L; Eickhoff SB; Abdulkadir A; Kaller CP; Peter J; Scheller E; Lahr J; Roos RA; Durr A; Leavitt BR; Tabrizi SJ; Klöppel S;
    Hum Brain Mapp; 2016 Jan; 37(1):67-80. PubMed ID: 26453902
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.
    Hellwig K; Kvartsberg H; Portelius E; Andreasson U; Oberstein TJ; Lewczuk P; Blennow K; Kornhuber J; Maler JM; Zetterberg H; Spitzer P
    Alzheimers Res Ther; 2015 Dec; 7():74. PubMed ID: 26698298
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease.
    De Vos A; Struyfs H; Jacobs D; Fransen E; Klewansky T; De Roeck E; Robberecht C; Van Broeckhoven C; Duyckaerts C; Engelborghs S; Vanmechelen E
    J Alzheimers Dis; 2016 Jul; 53(4):1523-38. PubMed ID: 27392859
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of variables associated with cerebrospinal fluid neurofilament, total-tau, and neurogranin.
    Mielke MM; Syrjanen JA; Blennow K; Zetterberg H; Skoog I; Vemuri P; Machulda MM; Graff-Radford J; Knopman DS; Jack CR; Petersen RC; Kern S
    Alzheimers Dement; 2019 Nov; 15(11):1437-1447. PubMed ID: 31668594
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Soluble TREM2 is elevated in Parkinson's disease subgroups with increased CSF tau.
    Wilson EN; Swarovski MS; Linortner P; Shahid M; Zuckerman AJ; Wang Q; Channappa D; Minhas PS; Mhatre SD; Plowey ED; Quinn JF; Zabetian CP; Tian L; Longo FM; Cholerton B; Montine TJ; Poston KL; Andreasson KI
    Brain; 2020 Mar; 143(3):932-943. PubMed ID: 32065223
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers.
    Casaletto KB; Elahi FM; Bettcher BM; Neuhaus J; Bendlin BB; Asthana S; Johnson SC; Yaffe K; Carlsson C; Blennow K; Zetterberg H; Kramer JH
    Neurology; 2017 Oct; 89(17):1782-1788. PubMed ID: 28939668
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Associations of Sleep Characteristics with Cerebrospinal Fluid sTREM2 in Cognitively Normal Older Adults: the CABLE Study.
    Hu HY; Ma LZ; Hu H; Bi YL; Ma YH; Shen XN; Ou YN; Dong Q; Tan L; Yu JT
    Neurotox Res; 2021 Aug; 39(4):1372-1380. PubMed ID: 34097185
    [TBL] [Abstract][Full Text] [Related]  

  • 53. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers.
    Suárez-Calvet M; Kleinberger G; Araque Caballero MÁ; Brendel M; Rominger A; Alcolea D; Fortea J; Lleó A; Blesa R; Gispert JD; Sánchez-Valle R; Antonell A; Rami L; Molinuevo JL; Brosseron F; Traschütz A; Heneka MT; Struyfs H; Engelborghs S; Sleegers K; Van Broeckhoven C; Zetterberg H; Nellgård B; Blennow K; Crispin A; Ewers M; Haass C
    EMBO Mol Med; 2016 May; 8(5):466-76. PubMed ID: 26941262
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum.
    Rauchmann BS; Schneider-Axmann T; Alexopoulos P; Perneczky R;
    Neurobiol Aging; 2019 Feb; 74():182-190. PubMed ID: 30458365
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TREM2 ectodomain and its soluble form in Alzheimer's disease.
    Yang J; Fu Z; Zhang X; Xiong M; Meng L; Zhang Z
    J Neuroinflammation; 2020 Jul; 17(1):204. PubMed ID: 32635934
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased CSF neurogranin concentration is specific to Alzheimer disease.
    Wellington H; Paterson RW; Portelius E; Törnqvist U; Magdalinou N; Fox NC; Blennow K; Schott JM; Zetterberg H
    Neurology; 2016 Mar; 86(9):829-35. PubMed ID: 26826204
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease.
    Squitieri F; Cannella M; Simonelli M; Sassone J; Martino T; Venditti E; Ciammola A; Colonnese C; Frati L; Ciarmiello A
    CNS Neurosci Ther; 2009; 15(1):1-11. PubMed ID: 19228174
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer's disease.
    Kvartsberg H; Lashley T; Murray CE; Brinkmalm G; Cullen NC; Höglund K; Zetterberg H; Blennow K; Portelius E
    Acta Neuropathol; 2019 Jan; 137(1):89-102. PubMed ID: 30244311
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cerebrospinal fluid levels of proenkephalin and prodynorphin are differentially altered in Huntington's and Parkinson's disease.
    Barschke P; Abu-Rumeileh S; Al Shweiki MHDR; Barba L; Paolini Paoletti F; Oeckl P; Steinacker P; Halbgebauer S; Gaetani L; Lewerenz J; Ludolph AC; Landwehrmeyer GB; Parnetti L; Otto M
    J Neurol; 2022 Sep; 269(9):5136-5143. PubMed ID: 35737109
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington's disease.
    Constantinescu R; Romer M; Oakes D; Rosengren L; Kieburtz K
    Parkinsonism Relat Disord; 2009 Mar; 15(3):245-8. PubMed ID: 19056308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.